---
title: "This Plexus Analyst Turns Bullish; Here Are Top 5 Upgrades For Tuesday"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/299767059.md"
description: "Wall Street analysts upgraded five stocks on Tuesday: MetLife (MET) to Overweight with a $110 target, Brinker International (EAT) to Buy with a $275 target, Plexus Corp (PLXS) to Overweight with a $300 target, West Pharmaceutical Services (WST) to Overweight with a $400 target, and Omeros Corp (OMER) to Overweight with a $22 target. Piper Sandler, Northcoast Research, Keybanc, Morgan Stanley, and Cantor Fitzgerald made these rating changes."
datetime: "2026-09-22T12:20:31.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/299767059.md)
  - [en](https://longbridge.com/en/news/299767059.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/299767059.md)
generator: "portal-rs"
---

# This Plexus Analyst Turns Bullish; Here Are Top 5 Upgrades For Tuesday

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our analyst ratings page.

-   Piper Sandler analyst Paul Newsome upgraded **Metlife Inc** (NYSE:MET) from Neutral to Overweight and raised the price target from $99 to $110. MetLife closed at $96.64 on Monday. See how other analysts view this stock.
-   Northcoast Research analyst Jim Sanderson upgraded **Brinker International Inc** (NYSE:EAT) from Neutral to Buy and announced a $275 price target. Brinker International shares closed at $200.30 on Friday. See how other analysts view this stock.
-   Keybanc analyst Steve Barger upgraded **Plexus Corp** (NASDAQ:PLXS) from Sector Weight to Overweight and announced a $300 price target. Plexus closed at $252.36 on Monday. See how other analysts view this stock.
-   Morgan Stanley analyst Kallum Titchmarsh upgraded **West Pharmaceutical Services Inc** (NYSE:WST) from Equal-Weight to Overweight and boosted the price target from $365 to $400. West Pharmaceutical shares closed at $361.78 on Monday. See how other analysts view this stock.
-   Cantor Fitzgerald analyst Olivia Brayer Saunders upgraded **Omeros Corp** (NASDAQ:OMER) from Neutral to Overweight and announced a $22 price target. Omeros closed at $18.49 on Monday. See how other analysts view this stock.

Considering buying PLXS stock? Here’s what analysts think:

*Photo via Shutterstock*

### Related Stocks

- [WST.US](https://longbridge.com/en/quote/WST.US.md)
- [MET.US](https://longbridge.com/en/quote/MET.US.md)
- [EAT.US](https://longbridge.com/en/quote/EAT.US.md)
- [OMER.US](https://longbridge.com/en/quote/OMER.US.md)
- [PLXS.US](https://longbridge.com/en/quote/PLXS.US.md)
- [MET-A.US](https://longbridge.com/en/quote/MET-A.US.md)
- [MET-F.US](https://longbridge.com/en/quote/MET-F.US.md)
- [MET-E.US](https://longbridge.com/en/quote/MET-E.US.md)

## Related News & Research

- [Is Brinker International (EAT) Undervalued After Raising Guidance And Posting Strong First Quarter Growth?](https://longbridge.com/en/news/304762170.md)
- [MetLife (MET) Stock Looks Reasonable Even With A 40% Value Gap](https://longbridge.com/en/news/304532512.md)
- [Plexus (PLXS) On Strong Results And Guidance Still Looks Undervalued](https://longbridge.com/en/news/305168073.md)
- [MetLife amends $4 billion credit agreement with Bank of America-led lenders](https://longbridge.com/en/news/304998761.md)
- [Omeros (OMER) Projected to Release Earnings on Thursday](https://longbridge.com/en/news/304416110.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**